Vitamins
Niacin for Skin: Evidence-Backed Benefits and Realistic Expectations
Niacinamide, the skin-active form of vitamin B3, has quietly become one of the most evidence-backed topical and oral ingredients in dermatology — yet most people don't know how the clinical doses compare to what's actually in their supplements. Understanding what niacin can and cannot do for your skin could save you from both under-dosing and unrealistic expectations.

What Is Niacin and Why Does It Matter for Skin?
Niacin is the umbrella term for two related compounds: nicotinic acid and nicotinamide (also called niacinamide). Both are forms of vitamin B3, but they behave quite differently in the body — and for skin specifically, niacinamide is the form that has accumulated the strongest clinical evidence.
At the cellular level, niacin's relevance to skin comes down to NAD⁺ (nicotinamide adenine dinucleotide), a coenzyme central to DNA repair, energy metabolism, and the regulation of inflammatory signaling. Keratinocytes — the cells that make up roughly 90% of the outer skin layer — are particularly dependent on NAD⁺ for barrier repair after UV exposure. When NAD⁺ availability drops, the skin's ability to recover from oxidative damage slows measurably (Surjana et al., Nutrients 2010; PMID: 22254051).
This isn't a minor biochemical footnote. It explains why niacinamide shows up in research on photoaging, hyperpigmentation, acne, rosacea, and eczema — these are all conditions with an inflammatory or barrier-repair component that NAD⁺-dependent pathways influence.
What the Clinical Evidence Actually Shows
The evidence base for niacinamide in skin health is unusually solid compared to most supplement ingredients. Here's what the controlled studies show:
Hyperpigmentation and uneven tone. A double-blind, randomized trial published in the British Journal of Dermatology found that 5% topical niacinamide applied for 8 weeks significantly reduced hyperpigmentation and increased skin lightness compared to vehicle control — the mechanism involves inhibiting melanosome transfer from melanocytes to keratinocytes, which is distinct from tyrosinase inhibition (Hakozaki et al., Br J Dermatol 2002; PMID: 12100180).
Skin barrier and transepidermal water loss (TEWL). A 6-week randomized trial in Japanese women demonstrated that topical 2% niacinamide significantly improved stratum corneum ceramide levels and reduced TEWL, supporting the role of niacinamide in upregulating the ceramide synthesis pathway (Tanno et al., Br J Dermatol 2000; PMID: 11069494).
Acne and sebum control. A comparative study published in the International Journal of Dermatology found that 4% niacinamide gel was as effective as 1% clindamycin gel in reducing inflammatory acne lesions over 8 weeks, without the antibiotic resistance concerns associated with topical antibiotics (Shahmoradi et al., Int J Dermatol 2013; PMID: 23688396).
Photoprotection and skin cancer prevention. Oral niacinamide at 500 mg twice daily (1,000 mg/day total) reduced the rate of new non-melanoma skin cancers by 23% in a phase 3 randomized controlled trial involving 386 high-risk participants over 12 months (Chen et al., N Engl J Med 2015; PMID: 26488693). This is one of the most clinically significant findings in the vitamin B3 literature and positions oral niacinamide as more than a cosmetic adjunct.
Rosacea and inflammation. Smaller trials have reported reductions in erythema and inflammatory papules with both topical and oral niacinamide, consistent with its known anti-inflammatory mechanism of downregulating NF-κB activation in keratinocytes (Dreizen et al., Cutis 1979 — foundational; and multiple subsequent observational studies).
| Outcome | Form | Dose | Duration | Effect | |
|---|---|---|---|---|---|
| Hyperpigmentation | Topical | 5% cream | 8 weeks | Significant lightening vs. vehicle | |
| Skin barrier / ceramides | Topical | 2% | 6 weeks | Reduced TEWL, increased ceramides | |
| Acne | Topical | 4% gel | 8 weeks | Equivalent to clindamycin 1% | |
| Skin cancer prevention | Oral | 500 mg BID | 12 months | 23% reduction in new lesions | |
| Rosacea erythema | Topical | 4% | 4–8 weeks | Reduced redness, papule count |
Realistic Expectations: What Niacin Won't Do
The evidence is compelling, but it has limits that are frequently glossed over in supplement marketing.
First, the distinction between topical and oral delivery matters enormously. Most of the skin-specific benefits in controlled trials come from topical niacinamide. When taken orally, niacinamide enters systemic circulation and must compete for uptake across multiple tissues. For skin barrier outcomes, there is currently less high-quality oral trial data than for topical application.
Second, flushing. Nicotinic acid (not niacinamide) causes the well-known niacin flush — prostaglandin-mediated vasodilation that produces redness, warmth, and tingling, particularly at doses above 50 mg. This reaction is sometimes confused with a skin benefit, but it's a pharmacological side effect, not a therapeutic mechanism. Niacinamide does not cause flushing.
Third, dose-dependency is real. The 500 mg twice-daily protocol in the skin cancer prevention trial is a clinical dose, not what's typically found in a standard B-complex. If you're taking a multivitamin with 20 mg of niacin, you're nowhere near the evidence-based range for skin photoprotection.
Fourth, timeline expectations. Visible pigmentation changes in controlled trials generally required a minimum of 8 weeks of consistent use. Barrier improvements developed over 4–6 weeks. Skin supplements are not fast-acting interventions.
Pregnenolone for Skin: Where the Evidence Stands
Pregnenolone is a steroid precursor hormone synthesized primarily in the adrenal cortex and brain. It serves as the upstream source for DHEA, progesterone, cortisol, and sex hormones. Its potential relevance to skin health relates to two mechanisms: its role in sebum regulation (sebaceous glands are steroidogenic) and its potential influence on skin collagen via downstream estrogen or progesterone pathways.
However, the evidence for pregnenolone specifically as a skin intervention is sparse and largely preclinical or anecdotal. Unlike niacinamide, there are no large randomized controlled trials demonstrating topical or oral pregnenolone's efficacy for measurable skin outcomes in humans. Animal models suggest steroidogenic pathways in skin exist and are relevant, but extrapolating this to human supplementation requires more data.
If you're exploring hormonal influences on skin quality — particularly perimenopausal skin changes — pregnenolone's downstream hormones (particularly estradiol) have more direct evidence. This isn't to dismiss pregnenolone, but to contextualize it: it's a plausible upstream modulator, not an evidence-confirmed skin treatment at this stage.
DIM for Skin: Estrogen Metabolism and Acne
DIM (diindolylmethane) is a compound derived from indole-3-carbinol, produced when you digest cruciferous vegetables. It modulates estrogen metabolism by shifting the ratio of 16-alpha-hydroxyestrone (a proliferative estrogen metabolite) toward 2-hydroxyestrone (a less proliferative metabolite). This metabolic shift is the basis for DIM's popularity in hormone-related skin concerns, particularly hormonal acne.
Hormonal acne — typically presenting along the jawline and chin — is frequently associated with androgen excess or estrogen-progesterone imbalance. DIM's ability to influence estrogen metabolism theoretically addresses one side of this hormonal equation.
The direct human trial data for DIM specifically on skin outcomes is limited, though a pilot study noted improvements in acne with oral DIM supplementation in women with confirmed hormonal imbalances. Its broader evidence base is in estrogen-sensitive cancer research rather than dermatology. If your acne has a confirmed hormonal driver (elevated androgens, estrogen dominance patterns on a hormone panel), DIM is a reasonable candidate to discuss with your clinician — but it won't replicate the effect of niacinamide on inflammation or barrier function and addresses a different mechanism entirely.
If you're managing cholesterol or cardiovascular markers alongside skin health, understanding how to lower LDL without medication may also be relevant, since some hormonal interventions have downstream lipid effects.
Inositol and Myo-Inositol for Skin
Inositol — particularly myo-inositol, its most biologically active isomer — has gained significant traction in research on hormonal and metabolic conditions, particularly PCOS (polycystic ovary syndrome). Its relevance to skin comes primarily through two pathways: insulin sensitization and androgen reduction.
In PCOS, elevated insulin drives the ovaries to overproduce androgens like testosterone and DHEA-S. These androgens stimulate sebaceous glands, increasing sebum production and triggering inflammatory acne. Myo-inositol, often combined with D-chiro-inositol at a 40:1 ratio, has been shown in randomized trials to reduce fasting insulin, free testosterone, and androgen-related symptoms — including skin and hair manifestations — in women with PCOS (Unfer et al., Gynecol Endocrinol 2012; PMID: 22296306).
For skin specifically, a small randomized controlled trial demonstrated that myo-inositol 4g/day over 3 months significantly reduced acne lesion counts in women with PCOS compared to placebo, alongside measurable reductions in androgen markers.
What this means practically: inositol's benefit for skin is conditional on the upstream hormonal driver being present. If your acne or excess sebum is driven by insulin resistance and androgen excess, myo-inositol addresses the root mechanism. If your skin concerns are UV-related, barrier-related, or pigmentation-related, inositol isn't the right tool — niacinamide is.
If you have elevated A1C or insulin resistance markers alongside skin concerns, the connection is worth exploring — there's good reason to understand what supplements can affect A1C if metabolic drivers are influencing your skin.
Myo-Inositol for Skin: The Insulin-Androgen Connection Explained
Myo-inositol's mechanism deserves a closer look because it illustrates how metabolic health and skin health are more integrated than most people realize.
Insulin resistance causes compensatory hyperinsulinemia — chronically elevated insulin. Insulin stimulates ovarian theca cells to produce androgens, and also increases IGF-1 signaling in sebaceous glands directly. The result is a biochemical environment that reliably worsens acne, particularly inflammatory, cystic acne that doesn't respond well to topical treatments alone.
Myo-inositol acts as an insulin second messenger, improving insulin receptor sensitivity without increasing insulin secretion. This reduction in insulin signaling reduces androgen stimulation at the sebaceous gland level. It's a mechanistically coherent pathway, backed by clinical trial data in a relevant population (PCOS women, who have this exact metabolic pattern).
The practical implication: if you've had blood work showing elevated fasting insulin, elevated DHEA-S, or a formal PCOS diagnosis, myo-inositol is one of the more evidence-grounded supplement options for the skin consequences of that metabolic profile. For anyone managing A1C or blood glucose, the overlap with skin health is worth noting — lowering A1C without medication often involves the same insulin-sensitizing strategies.
The clinical dose used in most positive PCOS trials is 2–4g of myo-inositol daily, often divided into two doses.
What This Means for Your Formula
Niacinamide's evidence profile makes it one of the more justifiable nutrients to include in a personalized formula oriented toward skin health, particularly when blood work or wearable data suggest oxidative stress, elevated inflammatory markers, or suboptimal B-vitamin status.
At Ones, the AI health practitioner looks at your full data picture — including labs, skin concerns you've flagged, and metabolic markers — before building your formula. This matters because niacinamide's benefit for skin is highly conditional: it's most relevant if you have photoaging concerns, hyperpigmentation, or barrier dysfunction, while myo-inositol becomes the more targeted choice if your blood work shows insulin resistance or androgen elevation driving hormonal acne.
Specific Ones ingredients that may appear in a skin-supportive formula depending on your data:
- Zinc (as zinc bisglycinate): Clinical doses of 30–45 mg/day have demonstrated meaningful reductions in inflammatory acne in head-to-head trials against antibiotics, particularly in acne with an inflammatory phenotype. Ones sources zinc at clinical-range doses, not the trace amounts in standard multivitamins.
- Omega-3 (EPA/DHA): EPA specifically has demonstrated anti-inflammatory effects in sebaceous glands in randomized trials, with meaningful reductions in inflammatory lesions at doses of 1,000–2,000 mg EPA/day. The lipid-modulating effects of omega-3 are relevant for both skin and cardiovascular markers — if your lipid panel is off, understanding why total cholesterol stays elevated may be part of the same conversation.
- Vitamin D3 + K2 (MK-7): Vitamin D receptors are expressed in keratinocytes and sebaceous gland cells, and deficiency is independently associated with higher acne severity in observational data. D3 is included in many Ones formulas at doses calibrated to your blood level, not a one-size number.
The point isn't to stack every skin-relevant ingredient — it's to identify which mechanism is actually driving your skin concern and target that specifically.
Key Takeaways
- Niacinamide (vitamin B3) has the strongest clinical evidence for skin benefits, including hyperpigmentation reduction, barrier repair, acne control, and oral skin cancer prevention at 500 mg twice daily.
- Most skin benefits in controlled trials come from topical niacinamide, not oral supplementation — oral protocols require significantly higher doses than typical B-vitamin supplements provide.
- Pregnenolone for skin lacks direct human trial evidence; its theoretical mechanism via downstream hormones is plausible but not yet confirmed in controlled skin trials.
- DIM addresses estrogen metabolism, making it relevant for hormonally-driven acne with a confirmed estrogen-dominance pattern — not for barrier or pigmentation concerns.
- Myo-inositol is the right tool when insulin resistance and androgen excess are driving skin problems, particularly in PCOS; clinical doses of 2–4g/day show meaningful acne reductions in this population.
- Personalized lab data changes which of these ingredients is actually useful for you — the overlapping metabolic and hormonal drivers of skin health mean that blood work context matters more than a generic skin supplement stack.